Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Teva moves closer to a drug for celiac disease with positive Phase 2 results

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at calcalistech.com →

◆ Verified

Fusion42 · 2 September 2026 · Fusion42 review

Teva's experimental antibody TEV-408 showed positive Phase 2a results in preventing intestinal damage in celiac disease patients, with potential annual revenues estimated at $1 billion if approved. The drug targets the underlying immune cause by blocking IL-15 and has Fast Track designation from the FDA.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 2 Sep 2026 and 3 Sep 2026.

◆ ◆ The Wire takeaway

Your autoimmune drug strategy just gained a model for blocking root disease causes. If you develop treatments for chronic immune disorders, this signals a rising market for targeted biologics.

◆ Coverage

3 sources · first reported 2 Sep 2026 · latest 3 Sep 2026

◆ Related on Wire

◆ Topics

Biotechceliac-diseasebiotechclinical-trialsautoimmunedrug-development